Bio­Marin gene ther­a­py could be on hold 'for sev­er­al quar­ter­s' af­ter FDA man­dates new pre­clin­i­cal tests

The FDA is stay­ing cau­tious af­ter da­ta came out sug­gest­ing that one of Bio­Marin’s ex­per­i­men­tal gene ther­a­pies might have the po­ten­tial to dri­ve can­cers. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER